Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study was a one-year, community-based, multi-centre, randomised controlled trial assessing the degree to which a statin and/or omega-3 fatty acids reduce the estimated risk of coronary heart disease (CHD) in 1,000 people with Type 2 diabetes.


The results of the AFORRD trial were presented at the International Diabetes Federation Congress in Cape Town on Thursday 7th December 2006

[Read More]

Principal investigator

Rury Holman

Andrew Neil


Andrew Farmer


Pfizer Ltd

Reference number